Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, Fries W, Mendolaro M, Privitera AC, Ferracane C, Pisana V, Magnano A, Pluchino D, Inserra G, Scarpulla G, Garufi S, Carroccio A, Siringo S, Di Mitri R, Cottone M, Orlando A. Renna S, et al. Among authors: pluchino d. Dig Liver Dis. 2018 Dec;50(12):1292-1298. doi: 10.1016/j.dld.2018.06.008. Epub 2018 Jun 22. Dig Liver Dis. 2018. PMID: 30007516
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, Cappello M, Morreale GC, Siringo S, Privitera AC, Ferracane C, Belluardo N, Alberghina N, Ventimiglia M, Rizzuto G, Renna S, Cottone M, Orlando A. Macaluso FS, et al. Among authors: pluchino d. Dig Liver Dis. 2018 Jul;50(7):675-681. doi: 10.1016/j.dld.2018.02.013. Epub 2018 Mar 1. Dig Liver Dis. 2018. PMID: 29576495
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Cappello M, Scrivo B, Magnano A, Pluchino D, Camilleri S, Garufi S, Mitri RD, Mocciaro F, Magrì G, Ferracane C, Citrano M, Graziano F, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Macaluso FS, et al. Among authors: pluchino d. Dig Liver Dis. 2020 Dec;52(12):1461-1466. doi: 10.1016/j.dld.2020.06.014. Epub 2020 Jun 26. Dig Liver Dis. 2020. PMID: 32601033
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M, Guida L, Giuffrida E, Magnano A, Pluchino D, Ferracane C, Magrì G, Di Mitri R, Mocciaro F, Privitera AC, Camilleri S, Garufi S, Renna S, Casà A, Scrivo B, Ventimiglia M, Orlando A. Macaluso FS, et al. Among authors: pluchino d. Expert Opin Biol Ther. 2020 Nov;20(11):1381-1384. doi: 10.1080/14712598.2020.1830057. Epub 2020 Oct 9. Expert Opin Biol Ther. 2020. PMID: 32981373
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
Viola A, Muscianisi M, Macaluso FS, Ventimiglia M, Cappello M, Privitera AC, Magnano A, Pluchino D, Magrì G, Ferracane C, Mocciaro F, Garufi S, Giuffrida E, Costantino G, Fiocco G, Grova M, Guida L, Alibrandi A, Orlando A, Fries W; “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”. Viola A, et al. Among authors: pluchino d. JGH Open. 2021 Feb 2;5(3):364-370. doi: 10.1002/jgh3.12502. eCollection 2021 Mar. JGH Open. 2021. PMID: 33732883 Free PMC article.
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A; IG‐IBD LIVE Study Group. Pugliese D, et al. Among authors: pluchino d. Aliment Pharmacol Ther. 2022 Jul;56(1):95-109. doi: 10.1111/apt.16923. Epub 2022 May 12. Aliment Pharmacol Ther. 2022. PMID: 35876062 Free PMC article.
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS, Grova M, Mocciaro F, Di Mitri R, Privitera AC, Distefano ME, Vitello A, Camilleri S, Ferracane C, Pluchino D, Belluardo N, Giangreco E, Fries W, Viola A, Cappello M, D'Amato L, Bertolami C, Ventimiglia M, Renna S, Casà A, D'Antonio E, De Vivo S, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: pluchino d. J Gastroenterol Hepatol. 2023 Sep;38(9):1503-1509. doi: 10.1111/jgh.16208. Epub 2023 May 6. J Gastroenterol Hepatol. 2023. PMID: 37148148
Efficacy of 1 L polyethylene glycol plus ascorbate versus 4 L polyethylene glycol in split-dose for colonoscopy cleansing in out and inpatient: A multicentre, randomized trial (OVER 2019).
Vassallo R, Maida M, Zullo A, Venezia L, Montalbano L, Mitri RD, Peralta M, Virgilio C, Pallio S, Pluchino D, D'amore F, Santagati A, Sinagra E, Graceffa P, Nicosia G, Camilleri S, Gibiliaro G, Abdelhadi Y, Rancatore G, Scalisi G, Melita G, Magnano A, Conoscenti G, Facciorusso A; AIGO. Vassallo R, et al. Among authors: pluchino d. Dig Liver Dis. 2024 Mar;56(3):495-501. doi: 10.1016/j.dld.2023.07.032. Epub 2023 Aug 12. Dig Liver Dis. 2024. PMID: 37574430 Clinical Trial.